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Background: Palliative care remains suboptimal in end-stage liver disease. 
Aims: To inform a definitive study, we assessed palliative long-term abdominal 
drains in end-stage liver disease to determine recruitment, attrition, safety/ potential 
effectiveness, questionnaires/interview uptake/completion and make a preliminary 
cost comparison.                                                                                                        
Methods: A 12-week feasibility non-blinded randomised controlled trial comparing 
large volume paracentesis vs. long-term abdominal drains in refractory ascites due to 
end-stage liver disease with fortnightly home visits for clinical/questionnaire-based 
assessments. Study success criteria were attrition not >50%, <10% long-term 
abdominal drain removal due to complications, long-term abdominal drain group to 
spend < 50% ascites-related study time in hospital vs. large volume paracentesis 
group and 80% questionnaire/ interview uptake/completion.                                                                                                                           
Results: Of 59 eligible patients, 36 (61%) were randomised, 17 to long-term 
abdominal drain and 19 to large volume paracentesis. Following randomisation, 
median number (IQR) of hospital ascitic drains,  (long-term abdominal drain vs. large 
volume paracentesis group) were 0 (0,1) vs. 4 (3,7); week-12 serum albumin (g/L) 
and serum creatinine (μmol/L) were 29 (26.5,32.5) vs. 30 (25,35) and 104.5 
(81,115.5) vs.127 (63,158) respectively. Total attrition was 42% (long-term 
abdominal drain group 47%, large volume paracentesis group 37%). Median (IQR) 
fortnightly community/hospital/social care ascites-related costs and percentage study 
time in hospital were lower in the long-term abdominal drain group, £329 (253,580) 
vs. £843 (603, 1060) and 0% (0,0.74) vs. 2.75% (2.35,3.84) respectively. Self-limiting 
cellulitis/leakage occurred in 41% (7/17) in the long-term abdominal drain vs. 11% 
(2/19) in the large volume paracentesis group; peritonitis incidence was 6% (1/17) vs. 
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11% (2/19) respectively. Questionnaires/interview uptake/completion were >80%, 
interviews indicating that long-term abdominal drains could transform the care 
pathway. 
Conclusions: The REDUCe study demonstrates feasibility with preliminary evidence 
of long-term abdominal drain acceptability/effectiveness/safety and reduction in 
health resource utilisation.                                                           
Trial registration: ISRCTN30697116, date assigned: 07/10/2015 
Funder: National Institute for Health Research  
 




































Liver related deaths in England have increased by more than 250% since 1971, and 
now constitute the fourth commonest cause of premature death (1). Development of 
ascites is an important milestone in the natural history of cirrhosis, 20% presenting 
with ascites dying within the first year of the diagnosis (2). Refractory ascites, defined 
by intolerance or unresponsiveness to diuretics (3), is a useful prognostic indicator as 
median transplant-free survival is about six months (3-4). Liver transplantation is 
however only possible in a minority with refractory ascites (3,5).                                                                  
Based on reported exclusion criteria, a substantial number with refractory ascites are 
not candidates for trans jugular intrahepatic portosystemic shunts (TIPSS) and or the 
automated low flow ascites pump (3). The most common management for refractory 
ascites remains repeated hospitalisation for large volume paracentesis (LVP) (3). A 
British study (2013-2015) indicated that of the 45,000 cirrhosis related deaths, about a 
third required LVP in the last year of their life with overall healthcare costs being 
over £21,000 per person (6).                                                                                                                          
Long-term abdominal drains (LTAD) are tunnelled drains inserted in hospital under 
local anaesthetic, with community nurses/informal caregivers draining small amounts 
(1-2 litres) of ascitic fluid at home, up to three times a week (7-9). A National 
Institute for Health and Care Excellence technology guidance in malignant ascites 
reported that LTAD were clinically effective, had low complication rates and 
compared with inpatient LVP, resulted in cost savings of £679/patient at the cost of 
23.5 additional community nurse visits (8). Nationally, > 3500 LTAD (including 
PleurX™ and Rocket® drains) are inserted annually for malignant ascites (Richard 
Varey, Rocket Medical, personal communication). LTAD are not routinely used in 
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refractory ascites due to end-stage liver disease (ESLD), mainly due to infection risk, 
specifically peritonitis (3).                                                                        
Most patients (~ 75%) with ascites due to ESLD die in hospital (6) compared to 40% 
with advanced cancer (10). Despite potential benefits (11-12), less than a third of 
patients with ESLD are referred to palliative care services, which is often introduced 
late in the disease trajectory (13-14). To advance palliative care in ESLD, evidence is 
needed about effective interventions. To inform a definitive randomised controlled 
trial (RCT) including outcome measures, we conducted a feasibility study (REpeated 
Drainage in Untreatable ascites- REDUCe study). Our overarching aim was to 
improve palliative management of refractory ascites in ESLD.                                                                                                              
Patients and methods                                                                                                                                  
The study design for this three-year (Sept 2015-Sept 2018) feasibility parallel RCT 
comparing LTAD vs. LVP has been previously described (15). The study was 
conducted across five hospital and corresponding community sites in England.  
Refractory ascites was defined as ascites that could not be treated or early recurrence, 
which could not be prevented due to non-response to sodium restriction, diuretics and 
or development of diuretic induced complications that precluded use of an effective 
dose (3).  Our inclusion criteria were ascites that recurred rapidly after LVP, requiring 
one or more LVPs/month (participants undergoing a minimum of two LVPs prior to 
recruitment), age > 18 years, Child Pugh Score  > 9 (unless felt to be palliative despite 
lower CPS) and capacity to give informed consent. Study exclusion criteria were 
loculated or chylous ascites, presence of > grade 1 hepatic encephalopathy, evidence 
of active infection including spontaneous bacterial peritonitis during screening 
(supplementary fig 1) and eligibility for liver transplantation. Screening for infection 
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included urine dipstick and culture, blood culture and ascitic tap for 
polymorphonuclear count and culture (supplementary fig 1).  Potential participants 
could be rescreened for the study once the infection had been successfully treated. To 
avoid potential conflict of interest, transplant eligibility was determined at local 
multidisciplinary meetings (with discussion/review by a transplant centre if 
appropriate), and not by the research teams.  
Patient identification and Consent                                                                                                     
Patients were identified by Medical and Gastroenterology teams during the acute 
hospital admission or from those attending ascites day units. Once deemed to be 
transplant ineligible, a research team member provided a patient information sheet 
that included details of the LTAD insertion and after care process. Two-three days 
later, if willing, written informed consent was received from participants, and 
caregivers (if present). In the event that capacity for decision-making regarding trial 
participation was lost during study conduct, the participant’s nominated personal 
consultee (e.g. family member), and if unavailable, the participant’s medical 
consultant were approached. Ethical approval for the study was granted by the 
National Research Ethics Committee South Central - Hampshire A (REC ref 
15/SC/0257).                                                                                                        
Randomisation                                                                                                                                    
Patients fulfilling inclusion criteria were randomised (non-blinded) 1:1 to either 
Group 1: LTAD or Group 2: LVP using a web based system hosted by King’s 
Clinical Trials Unit. The allocations were revealed upon registering a participant and 
requesting their allocation and made by minimising, with a random element, on 
centre, Child Pugh Score and gender.                                                                                      
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Interventions                                                                                                                                        
Group 1: LTAD                                                                                                                                 
Rocket® (Rocket Medical, Watford, UK) LTAD insertion was performed in hospital 
as a day procedure under local anaesthetic using ultrasound guidance as previously 
described (15). Participants (and caregivers if present), community nursing teams, and 
primary care physicians were provided guidance on LTAD use (Rocket Medical 
provided additional support as needed). The community nurses visited the participants 
in their place of residence two-three times/week, draining 1-2 litres of ascitic fluid at 
each visit. No human albumin solution was administered.  
Group 2 Standard Care (LVP)                                                                                                     
Participants randomised to LVP (3) (the current standard of care) were admitted to 
day units or hospital (as per local practice) as clinically indicated. A peritoneal drain 
was inserted for up to six hours for ascites drainage and intravenous human albumin 
solution administered (8g -10g per litre of ascitic fluid removed) (3).                       
Antibiotic prophylaxis                                                                                               
There is no guidance on the use of prophylactic antibiotics in the setting of LTAD in 
ESLD. In fact, primary prophylaxis for spontaneous bacterial remains controversial 
and is the subject of ongoing studies (ASEPTIC, European Union Drug Regulating 
Authorities Clinical Trials Database Registration Number: 2019-000581-38). Both 
National Institute for Health and Care Excellence (16) and European Association for 
Study of Liver guidance (3) is to offer prophylactic antibiotics if total ascitic protein is 
15g/L or less. However recent studies suggest that ascitic fluid protein may not 
predict peritonitis rixk (17-18). Since refractory ascites indicates advanced liver 
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disease, we pragmatically offered all LTAD and LVP participants antibiotics 
(ciprofloxacin 500 mg once a day or equivalent), for the study duration.  
Each participant was followed up for up to 12 weeks (supplementary fig 1). 
Supplementary fig 2 shows participant timeline.                                                                                                       
Study objectives                                                                                                                                      
Since this was feasibility RCT, there were no predefined primary or secondary 
outcome measures. Rather our objectives were to explore recruitment; attrition rates; 
safety and potential effectiveness of LTAD; uptake/completion of 
questionnaires/interviews; quality of life, symptom and caregiver workload. The 
resource implications of LTAD and LVP were explored and a preliminary comparison 
of costs conducted. The acceptability of LTAD to patients and clinical staff were 
assessed using qualitative methods (optional). Our study success criteria were attrition 
not  > 50%; at least 80% uptake/completion of questionnaires/ interviews; those in the 
LTAD group to spend < 50% ascites-related study time in hospital compared to the 
LVP group; < 10% LTAD removal due to one or more of the following 
complications: failed insertion, peritonitis, bleeding and blockage (15).                                                                     
Schedule of Assessments and analysis                                                                                                     
For both groups there were fortnightly home visits by a research team member for 
data collection and assessments as previously described (15) (supplementary fig 1). 
Data were collected on paper case report forms and entered onto an electronic case 
report form within the Elsevier MACRO data capture system hosted by Kings Clinical 
Trials Unit.  
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Clinical                                                                                                                                                      
Data collected included demographics, biochemistry, number of ascitic drains 
performed before and after randomisation, use of diuretics, comorbidity, assessment 
of LTAD insertion site, amount and frequency of LTAD and LVP drainage after 
randomisation and any adverse events or serious adverse events. Reasons for 
transplant ineligibility were not formally recorded, though we would endeavor to do 
this in any subsequent definitive study.  Following discussion with our microbiology 
colleagues, we elected not to routinely culture the ascitic fluid from the LTAD due to 
the likelihood of growing skin contaminants. We took a pragmatic view to treat 
peritonitis if participants were symptomatic (fever, abdominal pain, hepatic 
decompensation, worsening renal function) and subsequent investigations revealed 
increased inflammatory markers, > 250/mm3 polymorphonuclear cells in the asctic tap 
and or a positive ascitic fluid culture (3). Our service users also considered it ethically 
inappropriate to treat asymptomatic patients since this was an end of life cohort, major 
goals being symptom control and avoiding hospitalisation.  
Questionnaire based assessments                                                                                                            
The rationales for instrument selection have been described previously (15).                   
a. Symptoms assessed fortnightly using the Integrated Palliative Outcome Scale 
(IPOS) (19-21). The patient version has 17 items and scores from 0 (best) to 68 
(worst). Besides a total score, the following subscale analyses were also performed as 
recommended in the recent validation study: physical symptoms, emotional symptoms 
and communication (21).                                                                                                                              
b. Liver specific health-related quality of life assessed every four weeks using the 
Short Form Liver Disease Quality of Life (SFLDQoL) (22). This has 75 disease-
targeted items transformed into the following domains on a scale of 0-100 (higher 
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score better quality of life): distress, stigma, memory, symptoms, sleep, hopelessness, 
effect of liver disease, loneliness and sex.                                                                                         
c. Generic health-related quality of life assessed every four weeks using EQ-5D-5L 
(23). This has a five item composite profile score (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression), scored on a 5 point scale and converted to 
an index value range (-0.59 (worst) to 1(best)) and a 20 cm vertical visual analogue 
scale with range 0 (worst) to 100 (best).                                                                                                                                
d. Caregiver workload assessed every four weeks using Zarit Burden Interview (ZBI-
12) (24-25). This has a 12 item composite scale completed by the caregiver with 
respect to negative feelings they experience in this role with 0 (never: best) to 48 
(nearly always: worst).                                                                                                       
Supplementary fig 1 shows the assessment schedule  
Resource use 
The main resource items were identified and collected at an individual patient level 
from two sources as described previously (15):  
- Hospital use was extracted from participants’ hospital records at the end of the 
study by research nurses in each site and transferred onto a bespoke proforma 
distinguishing drainage episodes as day case, inpatient or during a non-ascites 
related hospital admission. 
- Community and home-based service use assessed fortnightly using a modified 
version of the Ambulatory and Home Care Record (AHCR) (26) which was 
administered to participants/caregivers by a research team member. The 
AHCR asks for the number of contacts in and out of the home covering 
primary, secondary and social care professionals or services, and informal 
caring input (unpaid by family or friends), recorded as hours per day (on 
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average). Although participants/caregivers were asked to report hospital use, 
the data from hospital records were found to be more complete and were used 
in preference during analysis.                                                                                                 
The hospital and community databases were merged using the unique participant 
study numbers. Though data were collected on all service use both for hospital and 
community (liver and non-liver related), only ascites related service use was analysed 
further.  When ascites drainage occurred during a hospital admission for a non-ascites 
related indication, the day case tariff for a drainage procedure was applied. This tariff 
differs from the inpatient ascites procedure cost which was used when patients were 
admitted to hospital solely for drainage. Resources used were converted to costs 
(British pounds 2018) using nationally validated unit costs (27) and National Health 
Service reference costs (28). Time spent by informal caregivers was valued using 
replacement cost methods and applying the tariff for community support workers 
(26).                                                                  
Health economic analysis                                                                                                     
Since patients were in the study for different durations, and community data were 
gathered fortnightly (two-weekly), the data were standardised for fortnightly analysis. 
Where data were missing, research members were contacted for clarification.  
Resource use and costs for each main category are reported as mean + SD and median 
(range, IQR). The percentage study time spent in hospital for ascites drainage was 
calculated assuming 1 day for inpatient admissions solely for drainage and 0.5 days 
for day case procedures or if the patient had a drainage whilst in hospital for a non-
ascites related indication. 
Statistical analysis  
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As this was a feasibility study, 12 participants in each group was considered to be an 
adequate sample size (29); however, assuming a 50% attrition (30), the sample size 
was increased to 24 participants in each group. Descriptive statistics were used to 
summarise and compare the quantitative outcome measures. Data were summarised 
by group, as frequencies and percentages, mean + SD or median (IQR) with 95% 
confidence intervals presented for the estimated difference in means between groups 
at end of follow up. Analysis was performed on available cases following the 
intention to treat principle.                                                                                                    
Qualitative sub-study 
Detailed qualitative methods and results are being submitted for publication 
separately but are summarised here. A concurrent embedded qualitative study aimed 
to explore and contrast the experience, perceptions and care pathways of LTAD 
versus LVP participants. We aimed to interview 20 patients at diverse stages across 
the intervention, and eight healthcare professionals to assess similar areas as 
participant interviews but also focus on organisational/practical issues. All interviews 
were undertaken by telephone. Applied thematic analysis (31) supported by 
qualitative software (NVivo) (32) was used to extract overarching themes from 
interviews to capture participants' experiences and beliefs. These were considered in 
terms of a pathway approach towards accessing healthcare (33). 
 
Results                                                                                                                                     
Clinical outcomes                                                                                                                                 
The study commenced in Sept 2015, recruitment running from Nov 2015 – Jun 2018 
with 12 weeks of follow up. During the study period, of the 78 participants 
approached, 19 did not fulfil eligibility criteria (CONSORT fig 1a). Two were 
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initially regarded to be transplant ineligible at local multidisciplinary meetings but 
upon further review were deemed to be suitable for transplant assessment (fig 1a).  Of 
the 59 eligible, we randomised 36 (61%), i.e. 75% of our target sample size (n=48). 
These 36 participants accounted for approximately 32% of those undergoing two or 
more LVPs at the recruiting sites.  Of the eleven that declined to participate (fig 1a), 
five gave no reasons, three were not keen to be involved in research, one only wanted 
LTAD, one felt too unwell and one was unable to accept a limited life expectancy 
diagnosis. Nine out of 10 (90%) and 8/11 (73%) available caregivers in the LTAD 
and LVP groups respectively, were also successfully recruited.                                                                        
The LTAD insertion was performed by LMa at two sites and by interventional 
radiologists at the remaining three sites. All LTAD were successfully inserted, though 
one individual accidently pulled out the LTAD 24 hours after insertion. This 
participant declined to have it reinserted but was however willing to continue in the 
study.                                                                                                     
Table 1 shows baseline demographic and clinical data. The prevalence of hepatic 
encephalopathy, alcohol aetiology for ESLD and body mass index were higher in the 
LTAD group (table 1).  Of the 36 recruited, 35 had one or more absolute/relative 
contraindication for TIPSS as per European Association for Study of Liver guidelines 
(3), with one declining the procedure. Contraindications included serious co-
morbidity (n=25, 69%), age > 70 years (n=13, 36%), prior hepatic encephalopathy 
(n=9, 26%), Child Pugh C disease (n=7, 20%), hepatocellular cancer (n=6, 18%) and 
serum creatinine >1.5ULN (n=6, 17%).  
Ascites drainage data 
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Prior to randomisation, one participant has undergone two LVPs, the remainder 
undergoing three or more LVPs. 
After randomisation, data on further ascites drainage were available for 30/36 (83%) 
participants (15 in each group) as one site did not return service use data. Comparing 
LTAD vs. LVP groups, median (IQR) follow up (days) was 82 (53, 90) vs. 86 (75, 
92), median (IQR) amount of ascitic fluid (L) drained/week was 3.85 (2.85, 4.51) vs. 
4.42 litres (3.00, 6.09) and median (IQR) number of visits per week for drainage was 
1.9 (0.6, 2.5) vs. 0.33 (0.17, 0.5) respectively.                                                                                                     
Fig 1b shows the total number of ascitic drains in both groups before and after 
randomisation. In 10/15 (67%) of the LTAD participants, the ascites drainage was 
successfully conducted by community nurses or caregivers outside of hospital. The 
remaining five LTAD participants (including the one whose LTAD was pulled out) 
required 13 further ascitic drains in hospital. This included five non-ascites related 
hospital admissions when drainage was performed, and a further eight admissions in 
an ascites day unit (one admitted overnight for solely drainage). In the 15 LVP 
participants after randomisation, there were a further 69 ascitic drains (64 in an ascites 
day unit including one admitted overnight and four-non ascites related hospital 
admissions when drainage was performed). The median (IQR) number of ascitic 
drains before and after randomisation in LTAD vs. LVP group were 5 (3, 8) vs. 5 (4, 
7) and 0 (0, 1) vs. 4 (3, 7) respectively (fig 1b).  
Biochemical data  
Data was available in > 92% of participants at each visit except at week 10 in the LVP 
group (available in 85%). Baseline and week 12 serum albumin (g/L) (median, IQR),   
LTAD vs. LVP group were 33(33, 36) vs. 31(29, 34) and 29 (26.5, 32.5) vs. 30(25, 
35) respectively. Week 2 serum albumin declined in the LTAD group to 29.5 (27.5, 
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31.5), but this remained stable at end of study. Baseline and week 12 serum creatinine 
(μmol/L) (median, IQR), LTAD vs. LVP group was 109 (79, 141) vs. 113.5(89, 134) 
and 104.5 (81, 115.5) vs. 127 (63, 158) respectively. Figs 1c, 1d and 1e show the 
median (IQR) serum bilirubin (μmol/L), albumin (g/L) and serum creatinine (μmol/L) 
at each visit in both groups. Additional lab data (International Normalised Ratio) and 
liver prognostic scores (Child Pugh, United Kingdom End-stage Liver Disease, Model 
for End-stage Liver Disease) at each visit in both groups are shown in supplementary 
figs 3a, 3b, 3c and 3d respectively.  
Attrition                                                                                                                      
Overall attrition was 15/36 (42%), 95% CI (26, 59) - study withdrawal 3/15 (20%), 95% 
CI (4, 48) and death 12/15 (80%), 95% CI (52, 96) (seven in LTAD group and five in 
LVP group). Five out of the 12 deaths (42%) occurred within the first four weeks, 
three in LTAD and two in LVP group. Overall, 11/12 (92%) of the deaths were liver-
related. Of the 12 deaths, eight (67%), 95% CI (35, 90) occurred outside of hospital 
(four in each group). Median survival (days) in those who died, LTAD vs. LVP was 
53 (27, 70) vs. 61 days (26, 61) respectively. Overall 9/17 (53%) and 12/19 (63%) of 
the patients in the LTAD and LVP group respectively successfully completed the 
study. At the end of the study, all surviving LTAD participants elected to retain the  
drains.   
Questionnaire-based assessments                                                                                        
Table 2 shows data on EQ-5D-5L, IPOS (patient version) and ZBI-12 assessments 
and mean difference between the two groups at last follow up. Uptake of EQ-5D-5L 
at baseline and weeks 4, 8 and 12 was 97%, 86%, 85% and 95% respectively. IPOS 
(Patient) uptake at baseline and weeks 2, 4, 6, 8 and 12 was 97%, 94%, 89, 79%, 85%, 
88% and 95% respectively. Almost all questions were successfully completed at each 
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visit (table 2), Median physical, emotional, communication and total IPOS scores 
remained consistent throughout the study period in both groups. The EQ-5D-5L index 
worsened in the LTAD group with some improvement in the LVP group, though the 
EQ-5D-5L visual analogue scale showed a trend towards improvement in the LTAD 
groups. Only 47% of the participants (17/36) had carers available to complete the 
ZBI-12 questionnaire.  ZBI-12 scores remained stable in the LTAD group but there 
was an increasing trend (i.e. worsening carer burden) in the LVP group.                                
Table 3 shows data on SFLDQoL assessments and mean difference between the two 
groups at last follow up. Uptake of SFLDQoL at baseline, W4, W8 and W12 was 97%, 
82%, 81% and 86% respectively. Again most questions were successfully completed 
at each visit except 4/25 questions (16%) related to sexual function.  At baseline, 
LTAD group had higher scores (better quality of life) in all domains except 
loneliness.  During follow up scores increased in most domains in the LVP group 
though reduced in the LTAD group (i.e. worsening quality of life). 
Health economic outcomes                                                                                                    
Service use data were available for a total of 30/36 (83%) patients, 15 per group as 
one centre failed to return data.  The comparison of the resource use and costs 
(standardised to a fortnightly rate) related to ascites drainage are shown in 
supplementary table 1 and table 4 respectively. Unit costs used are listed in the 
footnote to table 4. Community nurse usage and costs were higher in the LTAD vs. 
LVP group (median of £168 vs. £0). This is reflected in higher overall community 
costs (median of £232 vs. £11).  LTAD participants also received higher median 
fortnightly social (£6 vs. £0) and informal care (£91 vs. £15) compared with the LVP 
group.  
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Of 82 hospital drainages, 13 were in LTAD (8 day cases) and 69 in LVP (64 day 
cases) group. Of the 10 inpatient drainages, 9 were during a non-ascites related- 
admission. The overall hospital costs were higher for the LVP vs. LTAD group 
(median £704 vs. £0).   
Taken together, the median fortnightly community, social and hospital costs were 
lower in the LTAD group (£329 vs. £843). The difference between groups on the 
overall total cost was less when informal care was included (£909 vs. £1057), as a 
result of the high variability in reporting of informal caring hours.  
Median (IQR) percentage ascites-related study time spent in hospital was also lower 
in the LTAD group, 0% (0, 0.74) vs. 2.75% (2.35,3.84). 
 
Adverse events and serious adverse events  
Table 5 shows the adverse and serious adverse events in both groups. Worsening renal 
function occurred in six and seven participants in the LTAD vs. LVP group 
respectively. There were seven participants with cellulitis/leakage post LTAD 
insertion (two with cellulitis, three with leakage and two with both cellulitis and 
leakage) and two with bleeding/leakage after LVP. All were minor and self-limiting 
with none requiring hospitalisation. Incidence of peritonitis was 1/17 (6%) vs. 2/19 
(11%) in LTAD vs. LVP group respectively, difference -5%, 95% CI (-24, 14). There 
were no LTAD related serious adverse events, none being removed after insertion due 




Of the 21 patients approached, 19 (90%) were willing to participate of whom five 
died rapidly. Therefore 14 patients (six allocated LTAD and eight LVP) and eight 
nurses (six community and two hospital) were interviewed, all interviews being 
completed. Themes that emerged included challenges of living with chronic ascites, 
recognising the need for drainage in hospital, organising hospital visits and waiting 
for discharge post drainage. Organisational barriers were perceived across this entire 
pathway. There was recognition, however, that ascites drainage provided relief (albeit 
temporarily).  
In contrast, LTAD appeared to transform this care pathway at all levels by mitigating 
practical challenges associated with navigating hospital services. Benefits beyond 
avoiding hospitalisation included improved symptom control and emotional support 
from regular home visits by community nurses. Interviews suggested that continuity 
of care across the community and hospital were key to these positive experiences by 
LTAD participants.   
LTAD participants reported acceptability of the drain insertion process and aftercare. 
However, one patient and two nurses reported temporary leakage problems resulting 
in embarrassment and distress. More than half of the LVP group who gave an opinion 
(5/8 participants) expressed disappointment at not being included in the LTAD arm. 
They were however, still willing to be randomised to LVP.  
Community nursing staff reported that LTAD were manageable within busy 
workloads. They nonetheless expressed concern that should LTAD be more widely 
adopted, additional resources would be required to deliver the service. Although 
patients had a limited life expectancy, nurses reported that some appeared not to have 
fully assimilated this information, and sometimes understood the LTAD to be part of 
ongoing active treatment rather than palliative care.                                                                                                       
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Discussion                                                                                                                                      
The REDUCe study demonstrates the feasibility to proceed to a full trial with no 
LTAD-related safety concerns, acceptability of intervention and assessment tools and 
reduced health resource utilisation and costs. Our study success criteria were achieved 
as attrition was 42%, uptake/completion of questionnaires/ interviews was > 80%, 
those in the LTAD group spent <50% ascites-related study time in hospital vs. LVP 
group and no LTAD were removed due to complications. Since the LTAD group did 
not routinely receive human albumin solution, serum albumin declined at week 2, but 
this then remained stable at the end of study.                                                                                                                                 
We have also shown potential LTAD effectiveness in refractory ascites due to ESLD 
that requires further evaluation in a definitive trial. Excluding those where ascites 
drainage was performed during a non-ascites-related hospital admission and the one 
individual whose LTAD was pulled out, only two LTAD participants required further 
hospital ascites drainage. In a recent systematic review on refractory ascites in ESLD, 
no further hospital admissions were required in 14/18 studies that reported drainage 
following LTAD insertion (34).  
As expected, community and social care costs were higher, and hospital costs lower 
for LTAD vs. LVP group.  Overall median LTAD costs were lower, although the  
group difference was less when informal caring costs were included, due to the high 
variability in informal caring hours reported by participants. Being research 
participants, individuals were closely monitored by staff who were aware of timely 
palliative care benefits. Consequently, about 70% of the deaths occurred outside 
hospital. In a real world setting cost saving could be greater as the majority with 
ESLD would be expected to die in hospital (6, 35). A recent study reported that 
patients with liver disease were twofold more likely to die in an institution with 15% 
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higher costs (p < .001), compared to those without liver disease (36). Since collection 
of EQ-5D-5L data was feasible, quality adjusted life years could be calculated in a 
larger study. Use of quality adjusted life years in palliative care remains controversial, 
due to problems with conceptualising quality of life, restrictions in life years gained 
and valuation of time. However, they are widely used and until alternative measures 
are available, it is reasonable that use of quality adjusted life years should continue 
(37-38).  
 Results from a recent national survey amongst Hepatologists/ Gastroenterologists, 
indicate that though almost all were willing to consider LTAD in ESLD, main 
deterrents were infection risk (90%) and community management (57%) (Dr Sushma 
Saxsena, Consultant Hepatologist, personal communication). We did not observe a 
higher peritonitis incidence in the LTAD group, though this was a feasibility study 
without a post hoc analysis (39). Our results are however consistent with an earlier 
systematic review (32), where peritonitis rates (12.7%) were no higher than what 
would be expected in ESLD (3).  
Consistent with earlier studies in ESLD  (40-41), we found high symptom burden and 
poor quality of life in our cohort. Our observed IPOS scores were similar to those 
reported in non-hepatic malignancy (19). Our ZBI scores were in fact higher than 
those seen in patients with hepatic encephalopathy (42) but similar to other advanced 
conditions such as glioblastoma (43) and heart failure (44). While accepting that this 
feasibility study was not powered to detect statistical differences, we observed most 
quality of life domains to worsen in the LTAD cohort. This was despite interviews 
indicating LTAD acceptability and improved symptom control. LTAD studies in 
malignant ascites also report inconsistent quality of life improvement during 
questionnaire-based assessments despite supportive qualitative data (8-9). These 
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incongruous results could be explained by absence of a validated ascites quality of life 
questionnaire and the incurable nature of refractory ascites, the LTAD being a 
constant reminder of a palliative intervention (9). The ASQoL study is trying to 
develop and validate an ascites-specific QoL questionnaire (Rajiv Jalan personal 
communication).  
Challenges in conducting clinical trials in a palliative setting include defining when 
the palliative phase of an illness has been reached, recruitment, high attrition, and 
uncertainty around appropriate assessment tools and outcome measures, contributing 
to a low overall reporting quality (45). MORECare guidance on evaluating complex 
interventions at the end of life recommends a mixed methods approach and recruiting 
patients who are likely to benefit most from the intervention, thus ensuring equipoise 
(46). In our study, participants were often referred late in the disease trajectory with 
15% dying prior to study inclusion and a further 40% dying within four weeks of 
recruitment. 
Lessons learnt to improve recruitment in future studies include dedicated 
multidisciplinary meetings to aid early identification of ESLD, not excluding those 
with hepatic encephalopathy and timely engagement between community nurses 
supporting the intervention delivery and research staff at recruiting sites. Additionally, 
ensuring appropriate funding for research home visits would enable prompt site set up 
and follow up data collection. Implementation of these strategies more than doubled 
our recruitment in years two and three (supplementary fig 4). We aim to conduct a 
future definitive study, designed as a non-inferiority trial for peritonitis incidence, 
with quality of life as one of the secondary outcomes. The sample size will be 
approximately 300, to be recruited from 40 sites nationally. As in the feasibility study, 
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all participants will receive prophylactic antibiotics for the study duration 
(ciprofloxacin 750 mg weekly). 
Our study did have limitations. It was a feasibility RCT with 56% of the participants 
recruited from a single site; hence, it lacks generalisability and external validity to 
support a national change in service delivery. Additionally, the incidence of self-
limiting cellulitis/leakage was higher in the LTAD group, though with increasing 
expertise in LTAD insertion, this may reduce. Secondly, primary spontaneous 
bacterial peritonitis prophylaxis could have potentially resulted in a falsely low 
peritonitis incidence in the LVP group; however our observed incidence (11%) did 
not reflect that (3). Thirdly, health economic data were missing from one site (17% of 
participants) and the small sample resulted in substantial range in costs, hence data 
need be interpreted with caution. Finally, we recruited only 75% of our target sample 
size, consistent with an earlier palliative trial in ESLD (47).  
In conclusion, the REDUCe study provides preliminary evidence of LTAD 
acceptability and safety in ESLD, with reduction in health resource utilisation, 
indicating feasibility to proceed to a definitive study. Trials focussed on improving 
palliative care in this growing disenfranchised cohort are a priority. The REDUCe 
study could help inform such future research.  
 
Acknowledgement                                                                                                                                     
We are indebted to the study participants and caregivers. We would also like to 
acknowledge the Clinical Investigation Research Unit Brighton, and study teams at 
each site (supplementary file 1). This study was supported by the United Kingdom 
Clinical Research Collaboration-registered King's Clinical Trials Unit at King's 
Health Partners, which is part funded by the NIHR Biomedical Research Centre for 
 23 
Mental Health at South London and Maudsley NHS Foundation Trust and King's 
College London and the NIHR Evaluation, Trials and Studies Coordinating Centre. 
Funding 
LMa is funded by the National Institute for Health Research and Kent Surrey and 
Sussex Deanery, AH by the Dunhill Medical Trust and Kent Surrey and Sussex 
Deanery and CJE by a HEE/NIHR Senior Clinical Lectureship. This manuscript 
presents independent research funded by the National Institute for Health Research   
under its Research for Patient Benefit Programme (Grant Reference Number PB-PG-
0214-33068). The views expressed are those of the author(s) and not necessarily those 
of the National Institute for Health Research or the Department of Health and Social 
Care. 
Conflict of interest for or all authors pertaining to this manuscript: none 
 Rocket Medical (Imperial Way, Watford, Herts WD24 4XX) provided the LTAD 
free of cost for the trial. Rocket Medical were not involved in the study design, data 
collection, manuscript preparation, nor will they claim any intellectual property based 
on this trial. 
Author contribution 
 LMa recruitment, LTAD insertion, data collection; ST, DS, MW, PI, MA, NP, AH 
recruitment and data collection; HG, MT, PW health economics; DL database set up 
and data entry; SB statistical analysis; CJE mixed methods and community 
perspective; SS service user input; LM conceived original idea; SV conceived original 
idea and funding lead applicant. SV wrote the initial draft with input from LMa, LM,  
HG, SB, DC; all co-authors contributed to and approved the final manuscript draft. 




Fig 1a. CONSORT flow chart 
Fig 1b. Total number of ascitic drains before and after randomisation in long-term 
abdominal drain (LTAD) and large volume paracentesis (LVP) group 
Fig 1c.  Median (IQR) serum bilirubin (μmol/L) in the long-term abdominal drain 
(LTAD) and large volume paracentesis (LVP) group at each visit 
Fig 1d. Median (IQR) serum albumin (g/L) in the long-term abdominal drain (LTAD) 
and large volume paracentesis (LVP) group at each visit   
Fig 1e. Median (IQR) serum creatinine (μmol/L) in the long-term abdominal drain 
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Table 1. Baseline demographic and clinical data in the long-term abdominal drain (LTAD) and large volume paracentesis (LVP)  
 
 LTAD (n=17) LVP (n=19) 
  n mean/med (%) SD/IQR n mean/med (%) SD/IQR 
Age (years) 17 66.3 10.4 19 67.9 12 
Female  4/17 (24%)   5/19 (26%)  
White British  16/17 (94%)   19/19 (100%)  
BMI (kg/m2) 16 28.4 22.2, 32.5 15 24.6 22.1, 28.9 
Serious comorbidity  11/17 (65%)   14/19 (74%)  
Prescribed Furosemide  5/17 (29%)   6/19 (32%)  
Prescribed Spironolactone  12/17 (71%)   11/19 (58%)  
Ongoing alcohol/drug use 5/17 (29%)   2/19 (11%)  
Child Pugh A  0/17 (0%)   1/18 (6%)  
Child Pugh B  14/17 (82%)   13/18 (72%)  
Child Pugh C  3/17 (18%)   4/18 (22%)  
MELD Score 17 13.8 4.5 18 16.3 7.3 
UKELD Score 17 54 4.5 18 54.1 6.2 
Bilirubin (μmol/L) 17 22 15, 37 18 23 17, 48 
Bilirubin > 33μmol/L 17 6/17 (35%)  18 7/18 (39%)  
Albumin (g/L) 17 33 32, 36 18 31 27, 33 
Albumin < 35 g/L 12 12/17 (71%)  16 16/18 (89%)  
Serum creatinine (μmol/L) 17 109 79, 141 18 113.5 89, 135 
Serum creatinine > upper limit of 
normal. 17 9/17 (53%)  18 10/18 (56%)  
Sodium (mmol/L) 17 133 130, 138 18 133.5 129, 137 
Sodium < 135 (mmol/L)  11/17 (65%)   11/18 (61%)  
INR 17 1.3 1.2, 1.5 18 1.3 1.2, 1.4 
Platelet count (109/L) 17 167 103, 193 18 124 106, 151 
Prior variceal bleed  2/16 (13%)   4/18 (22%)  
Prior spontaneous bacterial 
peritonitis  1/15 (7%)   2/15 (13%)  
Prior hepatic encephalopathy  7/16 (44%)   2/18 (11%)  
Hepatocellular cancer  3/16 (19%)   3/18 (17%)  
Aetiology:  
alcohol  12/17 (71%)   9/19 (47%)  
Aetiology: viral  1/17 (6%)   1/19 (5%)  
Aetiology: non alcoholic fatty liver 
disease  7/17 (41%)   7/19 (37%)  
Aetiology: other *   3/17 (18%)     6/18 (33%)   
Follow up  (days)**  82 (52-90)   85 (64-92)  
Some had more than one aetiology for ESLD                                                                                                                               
Aetiology other LTAD: cryptogenic n =1, haemochromatosis n=1, nodular regenerating hyperplasia + alcohol n=1                                                                                                                                                      
Aetiology other LVP: cryptogenic n= 2, alpha 1 antitrypsin deficiency n= 2, Primary biliary cholangitis n= 1, nodular 
regenerating hyperplasia + alcohol n= 1                                                                                                                                                                                                        
**Due to delayed research visits (participant on holiday, non-availability of research staff), three participants, one in LTAD 






Table 2. Summary statistics for EQ-5D-5L, Integrated Patient Outcome Scale (IPOS) (Patient) and Zarit Burden Interview (ZBI-
12) questionnaires in the long-term abdominal drain (LTAD) and large volume paracentesis (LVP) group by time point  
 
 
Long-term abdominal drain (LTAD) 
(n=17) Large volume paracentesis LVP (n=19)   
 n/N mean SD Median IQR n/N Mean SD Median IQR 
Mean 
difference 95% CI 
EQ-5D-5L             
EQ-5D-5L Index             
Baseline 17/17 0.65 0.30 0.75 0.40 18/19 0.52 0.28 0.56 0.38   
Week 4 10/13 0.75 0.12 0.73 0.18 14/15 0.53 0.24 0.53 0.22   
Week 8 10/13 0.66 0.15 0.66 0.09 13/14 0.54 0.25 0.55 0.36   
Week 12 8/9 0.59 0.15 0.65 0.20 12/12 0.57 0.24 0.54 0.31 0.02 
(-0.18, 
0.22) 
             
EQ-5D-5L VAS             
Baseline 17/17 57.6 26.7 55.0 30.0 18/19 54.1 23.4 52.5 45.0   
Week 4 10/13 51.5 32.7 50.0 55.0 14/15 56.9 22.4 57.5 38.0   
Week 8 10/13 67.5 20.3 67.5 30.0 13/14 55.8 18.8 50.0 35.0   
Week 12 8/9 66.3 28.1 67.5 45.0 12/12 55.7 20.8 52.5 23.5 10.6 
(-9.2, 
30.4) 
             
Zarit Carer              
Baseline 9 17.9 9.4 14.0 6.0 8 14.6 8.4 17.0 12.5   
Week 4 5 20.8 8.6 18.0 8.0 6 14.8 8.1 13.5 9.0   
Week 8 5 20.6 10.5 22.0 17.0 3 20.0 11.1 18.0 22.0   
Week 12 3 18.0 11.5 17.0 23.0 5 20.0 3.7 19.0 3.0 -2.0 
(-15.1, 
11.1) 
             
IPOS-Physical             
Baseline 17/17 10.6 7.2 11 12 18/19 15.6 5.8 16 10   
Week 2 16/17 8.9 5.2 8 7.5 18/18 14.1 6 14 9   
Week 4 11/13 10.7 6.1 11 9 14/15 14.1 6.1 13.5 7   
Week 5 11/13 11.4 5.5 11 5 12/15 11.7 5.4 10 7.5   
Week 6 10/13 11.9 4.1 12.5 5 13/14 13.8 5.8 14 7   
Week 10 10/12 10.3 5.2 9.5 4 12/13 12.2 7.2 12.5 12.5   
Week 12 8/9 14 6.4 14.5 9 12/12 15.3 7.6 14 14 -1.3 
(-8.1, 
5.6) 
Week 14             
IPOS-Emotional             
Baseline 16/17 6.9 3.2 7.5 3 18/19 6.6 3.4 6 5   
Week 2 16/17 4.9 3.9 3.5 5 18/18 5.8 3.5 5.5 5   
Week 4 11/13 4.5 3.8 5 9 14/15 4.9 2.9 4.5 3   
Week 5 12/13 6.8 4.8 6.5 5.5 12/15 4.5 2.7 3.5 2.5   
Week 6 11/13 6.5 4.5 6 7 13/14 5.3 3.5 4 4   
Week 10 10/12 6.2 4.5 5.5 8 12/13 4.4 3.1 5 5.5   
Week 12 8/9 6.5 5.1 7.5 8.5 12/12 4.5 2 4 3 1.6 
(-1.4, 
5.4) 
             
IPOS-
Communication             
Baseline 17/17 2.4 2.9 1 5 18/19 2.4 2.6 2 4   
Week 2 16/17 2 2.2 1.5 4 17/18 2.8 2.8 3 4   
 30 
Week 4 11/13 1.7 2.7 1 3 14/15 2.1 2.4 1.5 4   
Week 5 11/13 2.9 2.7 2 3 12/15 1.9 2.2 2 1.5   
Week 6 11/13 2.9 2.2 3 3 13/14 2.2 2.6 1 4   
Week 10 10/12 1.8 2.1 1 2 12/13 2.3 2.3 2 3   
Week 12 8/9 2.4 2.4 2.5 3.5 12/12 1.8 2.1 1 2 0.6 
(-1.5, 
2.7) 
             
IPOS-Patient 
(Total)             
Baseline 16/17 19.2 8.9 20.5 15.5 18/19 24.5 9.8 22.5 15   
Week 2 16/17 15.9 8.4 14 10.5 17/18 22.6 10.1 21 17   
Week 4 11/13 17 10.4 15 13 14/15 21 9.7 20 8   
Week 5 10/13 21.2 10.2 17 7 12/15 18.1 8.5 14.5 12.5   
Week 6 10/13 21.3 7.8 21 6 13/14 21.3 10.1 23 14   
Week 10 10/12 18.3 8.2 18.5 12 12/13 18.8 10.9 19 18   




n/N number of patients completing questionnaires /number alive at each visit.  
Increasing EQ-5D-5L scores indicate better health outcome 
Increasing IPOS and ZB1-12 scores indicate higher symptom and carer burden respectively  



















Table 3.  Summary statistics for the Short Form Liver Disease Quality of Life (SFLDQoL) questionnaire in the long-term 
abdominal drain (LTAD) and large volume paracentesis (LVP) group by time point 
 
 LTAD (n=17) LVP (n=19)   
 n/N Mean SD Median IQR n/N Mean SD Median IQR 
Mean 
difference 95% CI 
Symptoms             
Baseline 17/17 64.5 19.8 70.0 26.7 18/19 49.8 23.1 45.0 36.7   
Week 4 9/13 65.6 30.1 83.3 36.7 14/15 52.1 20.1 55.0 23.3   
Week 8 10/13 58.6 21.4 56.7 26.7 13/14 48.7 18.9 50.0 20.0   
Week 12 8/9 54.6 21.2 45.0 36.7 10/12 53.3 20.7 58.3 36.7 1.3 
(-19.7, 
22.2) 
Effect             
Baseline 15/17 58.9 23.5 50.0 41.7 17/19 50.5 24.2 50.0 33.3   
Week 4 9/13 57.9 25.7 50.0 41.7 14/15 60.4 24.3 64.6 16.7   
Week 8 9/13 57.4 10.6 58.3 16.7 12/14 60.8 22.9 54.2 39.6   
Week 12 8/9 61.5 27.8 62.5 45.8 10/12 60.4 26.7 54.2 54.2 1.0 
(-26.3, 
28.4) 
Memory             
Baseline 17/17 74.6 23.3 75.0 37.5 18/19 67.0 27.9 68.8 56.3   
Week 4 9/13 81.3 26.0 100.0 31.3 14/15 68.9 25.1 75.0 43.8   
Week 8 10/13 71.3 24.0 71.9 50.0 13/14 65.4 26.3 68.8 37.5   
Week 12 8/9 64.8 28.7 68.8 46.9 10/12 74.4 19.9 81.3 37.5 -9.5 
(-33.8, 
14.7) 
Distress             
Baseline 17/17 47.1 39.7 37.5 87.5 18/19 37.5 30.0 31.3 50.0   
Week 4 9/13 58.3 41.9 62.5 75.0 14/15 50.9 28.8 50.0 37.5   
Week 8 10/13 58.8 31.2 56.3 25.0 12/14 49.0 29.4 43.8 31.3   
Week 12 8/9 35.9 39.8 25.0 68.8 10/12 58.8 32.8 56.3 75.0 -22.8 
(-59.0, 
13.4) 
Sleep             
Baseline 17/17 57.4 22.2 55.0 25.0 18/19 36.0 21.9 35.0 40.0   
Week 4 9/13 52.8 12.5 55.0 15.0 14/15 46.8 19.7 50.0 30.0   
Week 8 10/13 55.0 18.1 55.0 30.0 12/14 33.8 16.9 30.0 20.0   
Week 12 8/9 45.0 14.1 42.5 22.5 10/12 41.5 15.1 40.0 20.0 3.5 
(-11.3, 
18.3) 
Loneliness             
Baseline 17/17 67.1 19.3 75.0 25.0 18/19 72.8 31.5 85.0 45.0   
Week 4 9/13 70.0 26.3 80.0 35.0 14/15 73.6 26.3 80.0 35.0   
Week 8 10/13 65.5 18.3 65.0 30.0 12/14 72.5 30.9 85.0 55.0   
Week 12 8/9 51.9 30.1 57.5 57.5 10/12 89.0 15.6 95.0 15.0 -37.1 
(- 60.4, -
13.9) 
Hopelessness             
Baseline 17/17 50.0 26.5 50.0 41.7 18/19 43.1 24.6 50.0 33.3   
Week 4 9/13 55.6 26.7 58.3 33.3 14/15 48.2 20.2 50.0 16.7   
Week 8 9/13 45.4 27.7 50.0 33.3 12/14 47.9 24.7 50.0 45.8   
Week 12 8/9 29.2 27.1 20.8 41.7 10/12 48.3 17.9 50.0 33.3 -19.2 
(- 41.7, 
3.4) 
Stigma             
Baseline 17/17 66.4 28.7 62.5 50.0 18/19 61.8 24.2 62.5 37.5   
Week 4 9/13 54.9 25.5 56.3 31.3 14/15 68.3 24.1 75.0 37.5   
Week 8 9/13 63.9 30.3 68.8 50.0 12/14 70.8 25.2 78.1 46.9   




Sex             
Baseline 1/17 n/a n/a n/a n/a 1/19 n/a n/a n/a n/a   
Week 4 3/13 3.8 0.7 4.0 1.3 3/15 2.6 1.6 2.0 3.0   
Week 8 2/13 4.4 0.1 4.4 0.2 3/14 2.4 1.7 2.0 3.3   
Week 12 1/9 n/a n/a n/a n/a 1/12 n/a n/a n/a n/a n/a n/a 
n/N number of patients completing questionnaires/ number alive at each visit                                                                           






































Table 4. Cost per fortnight (British pounds 2018) in the long-term abdominal drain (LTAD) and large volume paracentesis (LVP) group 
Service  
 
Community / LTAD n=15 Hospital / LVP n=15 
Mean SD Median Range IQR Mean SD Median Range IQR 
District nurse  1.8 6.8 0 0, 26 0,0 0.70 2.7 0 0, 11 0, 0 
Community/ specialist nurse 160.1 79.1 168 0, 252 109, 224 24.3 57.5 0 0, 218 0, 31 
Palliative care nurse 36.1 97.5 6 0, 385 0, 26 16 33.7 0 0, 131 0, 22 
GP (home visits) 12.8 14.2 11 0, 37 0, 21 6.3 13 0 0, 37 0, 11 
Allied health professional 9 15.2 0 0, 53 0, 18 34 127.8 0 0, 496 0, 0 
Other health professional 5.3 18 0 0, 70 0, 0 25.2 96.3 0 0, 373 0, 0 
All community health 225.2 149.1 232 24, 660 109, 266 106.5 245.8 11 0, 921 0, 85 
Social care worker 76.6 123.1 6 0, 376 0, 122 22.1 66.4 0 0, 251 0, 0 
Day case drainage 74.6 174.3 0 0, 557 0, 0 663.1 316.4 704 0, 1057 463, 986 
Inpatient drainage 0 0 0 0, 0 0, 0 20.2 78.4 0 0, 303 0, 0 
Admitted to hospital for non 
ascites reasons and had 
drainage 
53.5 114.2 0 0, 333 0, 0 40.4 88.8 0 0, 291 0, 0 
Hospital total 128.2 227.8 0 0, 704 0, 188 723.7 289.2 704 173,1311 517, 986 
Informal care  759.9 984.5 91 0, 2433 0, 1370 685.1 1145.5 15 0, 3402 0, 1099 
Overall cost with informal 
care 
1189.8 937.9 909 174, 2877 567, 1631 1537.4 1193.8 1057 450, 4462 844, 1701 
Overall cost (excluding 
informal care) 
429.9 257.7 329 109, 957 253, 580 852.3 257.0 843 435, 1311 603, 1060 
 
Unit costs from Curtis and Burns 2018 (27):  District nurse, band 6, £37 per half hour patient related work, page 123; Community / specialist / palliative nurse, band 7, £43.50 per half hour patient related work, page 
123; GP home visit £74 per visit, assumes twice the cost of a consultation in the GP surgery/ office @£37 for 9.22 minutes, page 127; Allied Health Professionals (AHP) (physiotherapist, occupational therapist, speech 
and language therapist, dietician), average of 4 professions, £35 per half hour, page 18; other health professionals, assumed as AHPs; social care worker, £13.50 per half hours visit, page 143, home care worker; 
informal care – as social care worker, £27 per hour. Hospital ascites drainage, from NHS Improvement Reference costs 2018 (28): Day case £915.60, currency code YF04A (DC), also used when drainage was 





Table 5.  Adverse and serious adverse events in the long-term abdominal drain (LTAD) and large volume paracentesis (LVP) 
group  
Long-term abdominal drain group (LTAD) Large volume paracentesis group (LVP) 
Adverse event  Serious adverse event  Adverse event  Serious adverse event  
Abdominal pain (5) Fall (1) Abdominal pain (4) Abdominal pain (1) 
Nausea/Vomiting/diarrhoea/ 
constipation (7) 
Hospital acquired pneumonia (1) Nausea/Vomiting/diarrhoea/constip
ation (8) 
Hospital admission after LVP (1) 
Urinary tract infection  
(Klebsiella and E.coli) (2) 
Hepatic hydrothorax (1) Urinary tract infection (1) Leg fracture (1) 
 Sacral/vaginal/penis pain/skin 
laceration (6) 
SBP (1) Sacral pain/skin laceration (9) Hospital acquired pneumonia (1) 
Lower Respiratory tract/chest 
infection (3) 
Worsening renal function (2) Lower Respiratory tract infection 
(1) 
Hepatic hydrothorax (1) 
Falls (6) Hyperkalaemia (1) Fall (4) SBP (2) 
Hoarse voice (1) Worsening HE (1) Mouth ulcers (2) Worsening renal function (1) 
Oesophageal candida (1) Acute gastroenteritis (1) Epistaxis (2) Hyperkalaemia (1) 
Pruritus (1) Umbilical hernia leakage (1) Pruritus (1) Variceal bleed (2) 
Hypotension 1 Stroke (1) Increased ferritin (1) Death (5) 
Anaemia/GI bleed (2) Death (7) Cough/reflux (3)  
Hyperkalaemia (3)  Positive blood culture (S lutetiensis) 
(1) 
 
Worsening renal function (4)  Worsening renal function (6)  
Cellulitis /leakage at drain site (7)  Bleeding/leakage after LVP  (2)  
HE (3)  Hyponatremia/hypokalaemia (2)  
Worsening oedema/ 
breathlessness  (2) 
 Hypotension (1)  
Drain accidently pulled out (1)  Increasing bilirubin (1)  
  Fever (1)  
  Hospice admission (1)  
  Low energy/hypoglycaemia (2)  
  Umbilical hernia blister (1)  
  Anaemia/GI bleed (4)  
HE hepatic encephalopathy, GI Gastrointestinal; SBP Spontaneous bacterial peritonitis 
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